查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2017-2027年腫瘤學流式細胞分析技術市場 - 全球行業規模、佔有率、趨勢、機會及預測，按組件、按技術、按適應症、按應用、按最終用戶、按公司和按地區細分
市場調查報告書
商品編碼
1303138

2017-2027年腫瘤學流式細胞分析技術市場 - 全球行業規模、佔有率、趨勢、機會及預測，按組件、按技術、按適應症、按應用、按最終用戶、按公司和按地區細分

Flow Cytometry in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Indication, By Application, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在2023-2027年的預測期內，全球腫瘤學流式細胞分析技術市場預計將出現令人矚目的成長。主要因素包括癌症發生率的增加，流式細胞分析技術領域的技術發展，以及消費者對精準醫療和客製化治療意識的提高，推動市場的成長。流式細胞分析技術是一種基於生物物理和雷射的分析技術，在雷射束的幫助下，用於評估通常懸浮在液體中的細胞或膠束。這種技術有利於對細胞類型進行亞分類，並利用探針確定疾病的殘留水準，為病人制定有效的治療計劃。支持市場成長的其他因素有：癌症診斷領域的快速發展、研發活動的增加、血液惡性腫瘤的輸液量增加、流式細胞分析技術的採用率上升、與癌症有關的病例數量的指數上升、世界人口基數的上升、無機成長戰略的採用率上升以及慢性病的日益出現。

癌症和血液學惡性腫瘤發病率的上升

流式細胞分析技術用於診斷癌症和檢測最小殘留量。癌症發病率的成長，如肺癌、乳腺癌、胃癌、皮膚癌、喉癌和其他與血液有關的癌症，增強市場的成長。根據世衛組織的資料，2020年，癌症是突出的死亡原因，全球報告的死亡人數接近1000萬，或近六分之一的死亡。最常見的癌症是肺癌、結腸和直腸癌、乳腺癌和前列腺癌。另外，患有血液學惡性腫瘤的人數激增，如白血病、淋巴瘤和骨髓瘤，這些疾病需要流式細胞分析技術來診斷和檢測殘留物。根據美國癌症協會的資料，在美國，大約每3分鐘就有一人診斷出患有白血病、淋巴瘤和骨髓瘤。

消費者對客製化治療和精準藥物的認知不斷提高

消費者對精準醫療和客製化療法的認知不斷提高，促進了市場的成長。人們接受醫生的教育，了解與客製化療法和精準醫療有關的好處。精準醫學在治療各種癌症方面具有寶貴和巨大的潛力，促進了市場的成長。此外，政府為提高人們的認知而採取的各種計劃也促進了市場的成長。例如，2015年，美國推出了精準醫療計劃（PMI），該計劃旨在摒棄"一體適用"的醫療服務方式，根據人們的獨特個性，包括基因、生活方式和生物學，採用量身定做的治療和預防方法。

細胞測量儀器的技術發展支持市場成長

主要參與者越來越重視開發先進的流式細胞分析技術產品，提供易操作性，改進工作流程，快速讀取資料。由於細胞測量儀器的快速發展，採用流式細胞分析技術進行治療和監測癌症診斷的情況激增，這推動了市場的成長。例如，在2018年，默克公司推出了新的Cell Stream台式流式細胞分析技術系統，這是一個壓縮的、可客製化的流式細胞分析技術，使用相機進行檢測。透過這次推出，該公司擴展了其在流式細胞分析技術方面的產品線。

可用的客製化服務

透過給定的市場資料，TechSci Research根據公司的具體需求提供客製化服務。本報告有以下客製化選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和概況。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球腫瘤學流式細胞分析技術市場的影響

第五章：客戶的聲音

第六章：全球腫瘤學流式細胞分析技術的市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按組件（檢測和試劑盒、儀器、試劑和消耗品、軟體）分類
    • 按技術分類（基於細胞的 v/s 基於珠子的）
    • 按適應症（血液惡性腫瘤 v/s 固體腫瘤）
    • 按應用（轉化研究 v/s s 臨床應用）分類
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按地區
    • 按公司分類(2021年)
  • 市場地圖

第七章：北美腫瘤學流式細胞分析技術的市場前景

  • 市場規模和預測
    • 按價值分類
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按適應症分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 美國
    • 墨西哥

第8章：歐洲腫瘤學中的流式細胞分析技術市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按適應症分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第九章：亞太地區腫瘤學流式細胞分析技術的市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按適應症分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第十章：南美腫瘤學中的流式細胞分析技術市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按適應症分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲腫瘤學流式細胞分析技術的市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按適應症分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • MEA: 國家分析
    • 南非腫瘤學中的流式細胞分析技術
    • 沙烏地阿拉伯腫瘤學中的流式細胞分析技術
    • 阿拉伯聯合大公國腫瘤學中的流式細胞分析技術
    • 土耳其腫瘤學中的流式細胞分析技術
    • 埃及腫瘤學中的流式細胞分析技術

第十二章：市場動態

  • 驅動力
  • 挑戰

第十三章：市場趨勢與發展

第十四章：競爭格局

  • Agilent Technologies, Inc.
  • Apogee Flow Systems Ltd.
  • Becton, Dickinson and Company
  • bioAffinity Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cytognos, S.L.
  • Danaher Corporation
  • Miltenyi Biotec B.V. & Co. KG
  • Laboratory Corporation of America Holdings

第十五章：戰略建議

簡介目錄
Product Code: 13126

The global flow cytometry in the oncology market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing occurrences of cancer, technological evolution in the field of flow cytometry, and rising consumer awareness for precision medicine and tailored therapy are fueling the growth of the market. Flow cytometry is a biophysical and laser-based analytical technology that is used in the evaluation of cells or micelles that are generally suspended in a fluid with the help of a laser beam. This technique facilitates subclassifying cell types and identifying residual levels of disease using probes to develop an effective treatment plan for the patient. The other factors supporting the market's growth are rapid developments in the field of cancer diagnostics, rise in R&D activities, increasing fund infusions for hematological malignancies, rising adoption of flow cytometry instruments, the exponential rise in the number of cases associated with cancer, rise in world population base, growing adoption of inorganic growth strategies, and increasing emergence of chronic diseases.

Rising Prevalence of Cancer & Hematological Malignancies

Flow cytometry is used to diagnose cancer and detect minimal residue levels. Growing incidences of cancer, such as lung, breast, stomach, skin, throat, and other blood-related cancers, are augmenting the growth of the market. According to WHO, in 2020, cancer is a prominent cause of death, reporting nearly 10 million deaths globally, or nearly one in six deaths. The most common cancers are lung, colon and rectum, breast, and prostate cancers. Also, there is a surge in the number of people suffering from hematological malignancies such as leukemia, lymphoma, and myeloma, which need flow cytometry for the diagnosis and detection of residue. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma.

Growing Consumer Awareness for Tailored Therapy and Precision Medicines

The rising consumer awareness of precision medicine and tailored therapy is bolstering the growth of the market. People are being educated by doctors about the benefits associated with tailored therapy and precision medicine. Precision medicine has invaluable and enormous potential to cure various cancers, thus augmenting the growth of the market. Furthermore, various initiatives by the governments to raise awareness among people are facilitating the growth of the market. For instance, in 2015, The Precision Medicine Initiative (PMI) was launched in the US, an initiative to move away from the "one-size-fits-all" approach to health care delivery and to use tailor treatment and prevention approaches to people's unique individualities, including gene, lifestyle, and biology.

Technological Developments in Cytometry Instruments to Support Market Growth

Rising emphasis of key players on developing advanced flow cytometry products that offer ease in operability, improved workflows, and quick data reading. Owing to the rapid developments in cytometry instruments, the adoption of flow cytometers for therapeutic conducting and monitoring cancer diagnosis is surging, which propels the growth of the market. For instance, in 2018, Merck KGaA launched its new Cell Stream benchtop flow cytometry system, which is a compressed, customizable flow cytometer that uses a camera for detection. With this launch, the company has extended its product line in flow cytometers.

Market Segmentation

The global flow cytometry in the oncology market is segmented into component, technology, indication, application, end user, and company. Based on components, the market is divided into assays & kits, instruments, reagents & consumables, and software. Based on technology, the market is divided into cell-based and bead-based. Based on indication, the market is divided into hematological malignancies and solid tumors. Based on application, the market is divided into translational research and clinical applications. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and rising advancements in technology in the country.

Market Players

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec BV & Co. KG, and Laboratory Corporation of America Holdings are some of the leading companies operating in the market.

Report Scope

In this report, global flow cytometry in the oncology market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology Market, By Component:

  • Assays & Kits
  • Instruments
  • Reagents & Consumables
  • Software

Flow Cytometry in Oncology Market, By Technology:

  • Cell-Based
  • Bead Based

Flow Cytometry in Oncology Market, By Indication:

  • Hematological Malignancies
  • Solid Tumors

Flow Cytometry in Oncology Market, By Application:

  • Translational Research
  • Clinical Applications

Flow Cytometry in Oncology Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Flow Cytometry in Oncology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Flow Cytometry in Oncology Market

5. Voice of Customer

6. Global Flow Cytometry in Oncology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Assays & Kits, Instruments, Reagents & Consumables, Software)
    • 6.2.2. By Technology (Cell Based v/s Bead Based)
    • 6.2.3. By Indication (Hematological Malignancies v/s Solid Tumors)
    • 6.2.4. By Application (Translational Research v/s Clinical Applications)
    • 6.2.5. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 6.2.6. By Region
    • 6.2.7. By Company (2021)
  • 6.3. Market Map

7. North America Flow Cytometry in Oncology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Flow Cytometry in Oncology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Canada Flow Cytometry in Oncology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Mexico Flow Cytometry in Oncology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User

8. Europe Flow Cytometry in Oncology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Flow Cytometry in Oncology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Germany Flow Cytometry in Oncology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom Flow Cytometry in Oncology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy Flow Cytometry in Oncology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain Flow Cytometry in Oncology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Asia-Pacific Flow Cytometry in Oncology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Flow Cytometry in Oncology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. India Flow Cytometry in Oncology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Japan Flow Cytometry in Oncology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User
    • 9.3.4. South Korea Flow Cytometry in Oncology Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Indication
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia Flow Cytometry in Oncology Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Indication
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User

10. South America Flow Cytometry in Oncology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Indication
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Flow Cytometry in Oncology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina Flow Cytometry in Oncology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia Flow Cytometry in Oncology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Middle East and Africa Flow Cytometry in Oncology Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Indication
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Flow Cytometry in Oncology Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Indication
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia Flow Cytometry in Oncology Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Indication
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE Flow Cytometry in Oncology Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Indication
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User
    • 11.3.4. Turkey Flow Cytometry in Oncology Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Indication
        • 11.3.4.2.4. By Application
        • 11.3.4.2.5. By End User
    • 11.3.5. Egypt Flow Cytometry in Oncology Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Indication
        • 11.3.5.2.4. By Application
        • 11.3.5.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Agilent Technologies, Inc.
  • 14.2. Apogee Flow Systems Ltd.
  • 14.3. Becton, Dickinson and Company
  • 14.4. bioAffinity Technologies, Inc.
  • 14.5. Bio-Rad Laboratories, Inc.
  • 14.6. Bio-Techne Corporation
  • 14.7. Cytognos, S.L.
  • 14.8. Danaher Corporation
  • 14.9. Miltenyi Biotec B.V. & Co. KG
  • 14.10. Laboratory Corporation of America Holdings

15. Strategic Recommendations